A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX105 (Anti-PD-1 Antibody-IL-2 Variant Fusion Protein) in Advanced/Metastatic Solid Tumors
This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Waihan Ho
- 电话号码:+65-96253244
- 邮箱:Waihan_Ho@henlius.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Able to provide written informed consent and comply with study requirements.
- Aged 18-75 years.
- Histologically or cytologically confirmed advanced or metastatic solid tumors following failure of standard treatment, or for which no standard treatment is available.
- At least one measurable extracranial lesion according to RECIST v1.1.
- ECOG performance status of 0-1 and life expectancy greater than 3 months.
- Willing to provide adequate archived tumor tissue or undergo a tumor biopsy.
- Adequate organ function;
- Agreement to comply with protocol-defined contraception requirements during the study and for at least 6 months after the last dose.
Exclusion Criteria:
- Other malignancies within the past 2 years, except protocol-permitted early-stage cancers treated curatively.
- Prior IL-2/IL-15 therapy, or recent anticancer treatment, surgery, or live vaccination within protocol-defined washout periods.
- History of significant immunotherapy-related toxicity, severe allergic reactions, or allergy to HLX105 components.
- History or evidence of interstitial lung disease or other significant pulmonary conditions.
- Active infections, immunodeficiency, prior organ transplantation, or HBV/HCV infection meeting protocol-defined exclusion criteria.
- Significant cardiovascular, cerebrovascular, or thromboembolic disease.
- Brain metastases not meeting protocol-defined stability and eligibility requirements.
- Uncontrolled effusions or unresolved toxicity from prior treatment, except protocol-permitted conditions.
- Pregnancy or breastfeeding.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose Escalation
This study is an open-label first-in-human Phase I Clinical trial to evaluate the safety and tolerability of HLX105 with escalated doses in the treatment of participants with advanced/metastatic solid tumors. |
HLX105 will be administered as an intravenous(IV) infusion. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Dose-limiting toxicity (DLT)
大体时间:The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
|
Maximum tolerated dose(MTD)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
缓解持续时间 (DOR)
大体时间:最长约 2 年
|
最长约 2 年
|
|
|
Number of participants with adverse events(AEs)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Number of participants with serious adverse events(SAEs)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Objective response rate(ORR)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Disease control rate(DCR)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Progression-free survival(PFS)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Overall survival(OS)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Cmax
大体时间:Up to approximately 2 years
|
Maximum serum concentration (Cmax) of HLX105 |
Up to approximately 2 years
|
|
Tmax
大体时间:Up to approximately 2 years
|
Time to maximum serum concentration (Tmax) of HLX105 |
Up to approximately 2 years
|
|
T1/2
大体时间:Up to approximately 2 years
|
Half-life (T1/2) of HLX105 |
Up to approximately 2 years
|
|
Percentage of Participants With Anti-HLX105 Antibodies (ADA) and Percentage of Participants With Neutralizing Antibodies (NAb)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Change From Baseline in PD-1 Receptor Occupancy on Peripheral Blood T Cells
大体时间:Up to approximately 2 years
|
Receptor occupancy will be expressed as the percentage of PD-1 receptors occupied by the study drug. Changes from baseline will be calculated at each scheduled post-dose assessment. |
Up to approximately 2 years
|
|
Change From Baseline in Peripheral Blood Interferon Gamma Concentration
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- HLX105-FIH101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.